Caribou Biosciences (CRBU) Cash from Investing Activities (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash from Investing Activities data on file, last reported at $24.0 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 51.43% year-over-year to $24.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $76.8 million (down 32.02% YoY) and the FY2025 annual result came in at $102.2 million, up 18.05% from the prior year.
• Cash from Investing Activities improved to $24.0 million in Q1 2026 per CRBU's latest filing, from $18.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $49.4 million in Q1 2025 and bottomed at -$72.1 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is $15.9 million (2024), against an average of $3.0 million.
• The widest annual swing landed in 2022, when Cash from Investing Activities tumbled 327659.09%; it then surged 179.18% in 2023.
• Tracing CRBU's Cash from Investing Activities over 5 years: stood at $1.2 million in 2022, then plunged by 2790.09% to -$31.5 million in 2023, then surged by 150.61% to $15.9 million in 2024, then advanced by 12.81% to $18.0 million in 2025, then soared by 33.47% to $24.0 million in 2026.
• Per Business Quant, the three latest CRBU Cash from Investing Activities figures stand at $24.0 million (Q1 2026), $18.0 million (Q4 2025), and $10.9 million (Q3 2025).

Peer Comparison